Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: Psychedelic drugs have shown an efficacy in some psychiatric disorders and have an original mechanism of action with a 5-HT 2A agonism. Aim: The aim of this meta-analysis was to assess by a quantitative analysis the putative efficacy of psychedelic drugs on depressive symptoms and to investigate the kinetic of this efficacy. Methods: We searched the MEDLINE and PsycINFO databases through April 2019, without limits on year of publication. Means and standard deviations were extracted to calculate standardized mean differences (SMD). Scores of depressive symptoms were compared with baseline scores at days 7, 14, and 21; weeks 4–5 and 6–8; and months 3 and 6. Results: Eight studies were included in this meta-analysis. A significant decrease of depressive symptoms was found from day 1 ( n = 5 studies; SMD = ‒1.4, 95% confidence interval (CI): ‒2.33 to ‒0.48, p = 0.003) to 6 months ( n = 4 studies; SMD = ‒1.07, 95% CI: ‒1.44 to ‒0.7, p < 0.001) after psychedelic sessions. No serious adverse effect was reported in all included studies. A transient increase of the heart rate, blood systolic, and diastolic pressure were found after psychedelics compared with placebo. Conclusion: This meta-analysis shows that psychedelic treatments were safe and could contribute to a rapid improvement of depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 4×
“8% of patients achieved remission state after one line of selective serotonin recapture inhibition treatment (Rush et al., 2006).”
BackgroundInfluentialEvaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907 · cited 1×
“Quality assessment of the included studies was performed with the modified Newcastle-Ottawa Scale (Deeks et al., 2003) for open-label uncontrolled trials and with the Cochrane Collaboration’s Tool to assess the risk of bias (Higgins et al., 2003) for randomized doubled blind clinical trials.”
MethodGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 10×
“Four studies evaluated depressive symptoms in patients with life-threatening diseases (Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and four others evaluated depressive symptoms in patients with major depressive disorder (of which three studies included only…”
BackgroundInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 11×
“Five studies included in this meta-analysis used psilocybin (Carhart-Harris et al., 2018, 2016; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), two studies used ayahuasca (Palhano-Fontes et al., 2019; Sanches et al., 2016) and one study used LSD (Gasser et al., 2014).”
BackgroundInfluentialPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 17×
“Four studies evaluated depressive symptoms in patients with life-threatening diseases (Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and four others evaluated depressive symptoms in patients with major depressive disorder (of which three studies included only…”
BackgroundInfluentialNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 2×
“In healthy volunteers, psychedelic treatments have been associated with decreased activity of some hub regions of the DMN like the anterior cortex cingulate or medial prefrontal cortex and posterior cingulate cortex (Carhart-Harris et al., 2012; Palhano-Fontes et al., 2015) and with a modulation of the DMN connectivit…”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“…tobacco smokers with 80% of abstinence from smoking 6 months after two treatment sessions with psilocybin (Johnson et al., 2014) or in patients with an alcohol use disorder with a significantly reduced drinking behavior over 8 months after one or two psilocybin sessions (Bogenschutz et al., 2015).”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 1×
“Carhart-Harris et al. (2017) found a more surprising result showing an increase in default mode network (DMN) integrity in resting-state functional connectivity 1 day after psilocybin treatment and notably between ventromedial prefrontal cortex and infero-lateral parietal cortex which was…”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“…treatments in this therapy could allow a direct experience with altered cognitive and emotional states which could then be leveraged in ongoing counselling to ultimately challenge and replace maladaptive thoughts and behavioral patterns (Garcia-Romeu and Richards, 2018; Johnson et al., 2014).”
BackgroundInfluentialA meta‐analytic study of changes in brain activation in depression
Fitzgerald, P. B., Laird, A. R., Maller, J., & Daskalakis, Z. J. (2008) · Human Brain Mapping · doi:10.1002/hbm.20426 · Cited by 903
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · cited 17×
“In most studies, the placebo was a classical placebo (Palhano-Fontes et al., 2019) or an active placebo which could be a very low dose of psychedelic (Gasser et al., 2014; Griffiths et al., 2016), or niacin (Grob et al., 2011; Ross et al., 2016).”
BackgroundInfluentialRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 20×
“Four studies evaluated depressive symptoms in patients with life-threatening diseases (Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and four others evaluated depressive symptoms in patients with major depressive disorder (of which three studies included only…”
BackgroundMethodInfluentialPsilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587 · cited 1×
“Carhart-Harris et al. (2017) found a more surprising result showing an increase in default mode network (DMN) integrity in resting-state functional connectivity 1 day after psilocybin treatment and notably between ventromedial prefrontal cortex and infero-lateral parietal cortex which was…”
BackgroundMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 2×
“Indeed, very recently, an association between an acute psychedelic experience and serotonin 2A receptors occupancy was shown in healthy volunteers (Madsen et al., 2019).”
BackgroundSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 13×
“Email: brunoromeo@hotmail.fr towards a comfortable room with pleasing music (CarhartHarris et al., 2018, 2016; Griffiths et al., 2016; Grob et al., 2011; Palhano-Fontes et al., 2019; Sanches et al., 2016).”
BackgroundInfluentialPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Self-referential processing, rumination, and cortical midline structures in major depression
Nejad, A. B., Fossati, P., & Lemogne, C. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00666 · Cited by 366
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 2×
“Indeed, these drugs have an action on the serotoninergic system by a 5-HT1A/2A/2C agonism (Halberstadt, 2015).”
Backgrounddos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306 · cited 1×
“Psychedelic drugs showed an efficacy in some psychiatric disorders like substance use disorder (tobacco, alcohol), major depressive disorder (MDD) and obsessive-compulsive disorder (dos Santos et al., 2016).”
BackgroundClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · cited 1×
“Recently, a systematic review (Muttoni et al., 2019) on this topic suggests a potential efficacy of these treatments on depressive and anxious symptoms and a good tolerance.”
BackgroundSmigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248 · cited 2×
“, 2015) and with a modulation of the DMN connectivity which was associated with a positive change in psychosocial functioning (Smigielski et al., 2019).”
BackgroundMeta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Romeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.032 · Cited by 151 · cited 2×
“For the moment, only ketamine shows a relative similar kinetic of action (Romeo et al., 2015), however its mechanisms of action seem to be different.”
BackgroundResult
Cited by
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Metadata
- Authors
- Romeo, B., Karila, L., Martelli, C., & Benyamina, A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-05-25
- Volume
- 34
- Issue
- 10
- Pages
- 1079-1085
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3027835371
- Cited by
- 113
- References
- 25
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.